Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8109376 | 0.90 | PKM (0.41) | ALDH1A1PKMTSHRSMN1; SMN2PTGS1 | |
| SCHEMBL13424897 | 0.84 | — | — | |
| SCHEMBL13424894 | 0.84 | — | — | |
| SCHEMBL2231452 | 0.84 | — | — | |
| SCHEMBL14663224 | 0.81 | LMNA (0.44) | LMNAALDH1A1PKMTHRBTYMP | |
| SCHEMBL3424460 | 0.81 | PKM (0.40) | LMNAALDH1A1PKMTYMP | |
| SCHEMBL4172955 | 0.81 | PKM (0.35) | LMNAPKMCA2CA12CA9 | |
| SCHEMBL2604431 | 0.81 | CA12 (0.46) | LMNAALDH1A1PKMTSHRSMN1; SMN2 | |
| SCHEMBL17223962 | 0.81 | PKM (0.35) | PKMCA1CA2CA9 | |
| SCHEMBL6173378 | 0.81 | TSHR (0.44) | LMNAALDH1A1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-11310559-A | — | — | None | — | — | JP | disclosed |
| EP-3423539-B1 | COMPOSITION INCLUDING EPOXY ADHESIVE AND ALUMINUM FLAKES AND METHOD FOR MAKING THE SAME | 3M INNOVATIVE PROPERTIES CO (US) | 2020-11-18 | — | — | EP | disclosed |
| US-7691867-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2010-04-06 | — | — | US | disclosed |
| EP-1613619-B1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| US-20060270692-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | US | disclosed |
| EP-1613619-A1 | QUINAZOLINE DERIVATIVES FOR TREATMENT OF CANCER | AstraZeneca AB (SE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004094410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | WO | disclosed |
| JP-H11310559-A | N-ACYLIMINODICARBOXYLIC ACID COMPOUND,ANIONIC SURFACTANT, AND DETERGENT COMPOSITION CONTAINING THE SAME | LION CORP | 1999-11-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270692-A1 | Chemical compounds | CCNI, MKI67, TP53 | LMNA 704/4885ALDH1A1 402/4885PKM 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.